BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced the successful completion of raising approximately $11 Million in a Series pre-B2 financing. EdiGene’s Series A lead investor IDG Capital and Series pre-B lead investor Lilly Asia Ventures (LAV) invested in this round.
Separately, EdiGene has formed research collaboration with a clinical stage biopharmaceutical company developing novel T-cell therapies to explore new allogeneic T-cell therapeutic approaches for cancer. Company name and deal terms are not disclosed.
“Allogeneic T-cell therapeutics has tremendous potential in China and beyond, by offering innovative T-cell therapies “off the shelf” with more effective quality control and lower cost. We have been building the Allogeneic CAR-T Platform and this new research collaboration further demonstrates our commitment to develop such therapeutics to help the cancer patients in need,” said Dong Wei, Ph.D., MBA, CEO of EdiGene. “We are pleased to complete the new round of financing by our lead investors IDG and LAV. We look forward to working with them and other current investors to advance our exciting portfolio into the next stage.”
About EdiGene, Inc
EdiGene Inc is founded in 2015, and now headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA.
Our mission is to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery. We leverage our proprietary platforms to develop gene-editing therapies for a wide range of diseases, and to conduct high-throughput genome screening to enable dissection of functional big data in biological contexts.
More information can be found at www.edigene.com.